We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Agilent (A) Boosts LSAG Segment With New GPC/SEC Solutions
Read MoreHide Full Article
Agilent Technologies (A - Free Report) is constantly gaining traction in molecular analyses on the back of its strength in liquid chromatography mass spectrometry (LCMS) offerings.
This is evident from its latest InfinityLab Gel Permeation Chromatography/Size Exclusion Chromatography (GPC/SEC) solutions, which the company is gearing up to showcase at the HPLC 2023 conference.
With the new solutions, which are designed for advanced material characterization, the company strengthened its Agilent InfinityLab GPC/SEC portfolio. Moreover, the portfolio now includes the benefits of the Polymer Standard Service acquisition.
Notably, the new additions include the likes GPC/SEC column thermostat, the GPC/SEC-Ready Kit, a multi-angle light scattering detector and the powerful WinGPC Software.
The combined portfolio of InfinityLab GPC/SEC and Polymer Standard Service will help Agilent cater well to the needs of scientists in macromolecular analysis.
Also, it will aid its momentum across the chemical, food, pharmaceutical and biopharmaceutical industries.
The latest move bodes well for the company’s growing efforts toward bolstering its Life Sciences & Applied Markets Group (LSAG) segment, which contributes the most to total revenues.
Apart from the expansion of the Agilent InfinityLab GPC/SEC portfolio, the company recently launched the 6495 Triple Quadrupole LC/MS (LC/TQ) System and the Revident Quadrupole Time-of-Flight LC/MS (LC/QTOF) System.
Notably, 6495 LC/TQ is designed to take care of the critical transition between the discovery phase of research and the translational phase to generate meaningful scientific insights on the back of its intelligence features.
Meanwhile, Revident LC/Q-TOF features instrument intelligence for maximized operation time and productivity and a novel detection system that boosts spectral purity.
To Conclude
The abovementioned endeavors are expected to continue aiding the performance of the LSAG segment.
In second-quarter fiscal 2023, the underlined segment generated $968 million in revenues, which accounted for 56% of the total revenues. The figure was up 8% on a reported basis and 10% on a core basis from the prior-year fiscal quarter’s levels.
We believe the company’s strong focus on bolstering the LSAG segment will benefit its overall performance.
For fiscal 2023, Agilent expects revenues between $6.93 billion and $7.03 billion, implying growth of 1.2-2.7% on a reported basis and 3-4.5% on a core basis from the respective fiscal 2022 figures. The Zacks Consensus Estimate for Agilent's fiscal 2023 revenues is pegged at $6.99 billion, indicating growth of 2% from 2022.
However, mounting expenses do not bode well for the company’s profitability. Further, macroeconomic headwinds and uncertainties in the demand environment remain concerns.
Coming to price performance, Agilent has lost 20% in the year-to-date period against the industry’s growth of 4.5%.
Zacks Rank & Stocks to Consider
Currently, Agilent Technologies carries a Zacks Rank #4 (Sell).
Image: Bigstock
Agilent (A) Boosts LSAG Segment With New GPC/SEC Solutions
Agilent Technologies (A - Free Report) is constantly gaining traction in molecular analyses on the back of its strength in liquid chromatography mass spectrometry (LCMS) offerings.
This is evident from its latest InfinityLab Gel Permeation Chromatography/Size Exclusion Chromatography (GPC/SEC) solutions, which the company is gearing up to showcase at the HPLC 2023 conference.
With the new solutions, which are designed for advanced material characterization, the company strengthened its Agilent InfinityLab GPC/SEC portfolio. Moreover, the portfolio now includes the benefits of the Polymer Standard Service acquisition.
Notably, the new additions include the likes GPC/SEC column thermostat, the GPC/SEC-Ready Kit, a multi-angle light scattering detector and the powerful WinGPC Software.
The combined portfolio of InfinityLab GPC/SEC and Polymer Standard Service will help Agilent cater well to the needs of scientists in macromolecular analysis.
Also, it will aid its momentum across the chemical, food, pharmaceutical and biopharmaceutical industries.
Agilent Technologies, Inc. Price and Consensus
Agilent Technologies, Inc. price-consensus-chart | Agilent Technologies, Inc. Quote
LSAG Segment in Focus
The latest move bodes well for the company’s growing efforts toward bolstering its Life Sciences & Applied Markets Group (LSAG) segment, which contributes the most to total revenues.
Apart from the expansion of the Agilent InfinityLab GPC/SEC portfolio, the company recently launched the 6495 Triple Quadrupole LC/MS (LC/TQ) System and the Revident Quadrupole Time-of-Flight LC/MS (LC/QTOF) System.
Notably, 6495 LC/TQ is designed to take care of the critical transition between the discovery phase of research and the translational phase to generate meaningful scientific insights on the back of its intelligence features.
Meanwhile, Revident LC/Q-TOF features instrument intelligence for maximized operation time and productivity and a novel detection system that boosts spectral purity.
To Conclude
The abovementioned endeavors are expected to continue aiding the performance of the LSAG segment.
In second-quarter fiscal 2023, the underlined segment generated $968 million in revenues, which accounted for 56% of the total revenues. The figure was up 8% on a reported basis and 10% on a core basis from the prior-year fiscal quarter’s levels.
We believe the company’s strong focus on bolstering the LSAG segment will benefit its overall performance.
For fiscal 2023, Agilent expects revenues between $6.93 billion and $7.03 billion, implying growth of 1.2-2.7% on a reported basis and 3-4.5% on a core basis from the respective fiscal 2022 figures. The Zacks Consensus Estimate for Agilent's fiscal 2023 revenues is pegged at $6.99 billion, indicating growth of 2% from 2022.
However, mounting expenses do not bode well for the company’s profitability. Further, macroeconomic headwinds and uncertainties in the demand environment remain concerns.
Coming to price performance, Agilent has lost 20% in the year-to-date period against the industry’s growth of 4.5%.
Zacks Rank & Stocks to Consider
Currently, Agilent Technologies carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader technology sector are Palo Alto Networks (PANW - Free Report) , NVIDIA (NVDA - Free Report) and AMETEK (AME - Free Report) . While Palo Alto Networks and NVIDIA sport a Zacks Rank #1 (Strong Buy) each, AME carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Palo Alto Networks shares have gained 65% in the year-to-date period. The long-term earnings growth rate for PANW is currently projected at 31.5%.
NVIDIA shares rallied 173.8% in the year-to-date period. Its long-term earnings growth rate is presently projected at 23.02%.
AMETEK shares have increased by 10.2% in the year-to-date period. The long-term earnings growth rate for AME is currently projected at 8.95%.